Gaia Griguolo

Evolution of HER2-low expression from primary to recurrent breast cancer

Federica Miglietta, Gaia Griguolo, Michele Bottosso et al. · npj Breast Cancer · 2021 · 226 citations · Full text

Medicine, Oncology, Pathology +14

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

Aleix Prat, Tomás Pascual, Carmine De Angelis et al. · JNCI Journal of the National Cancer Institute · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

Aleix Prat, Valentina Guarneri, Tomás Pascual et al. · EBioMedicine · 2022 · 145 citations · Full text

Medicine, Bioinformatics, Oncology +17

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Fara Brasó‐Maristany, Gaia Griguolo, Tomás Pascual et al. · Nature Communications · 2020 · 118 citations · Full text

Medicine, Cancer Biology, Oncology +16

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy

Maria Vittoria Dieci, Gaia Griguolo, Michele Bottosso et al. · npj Breast Cancer · 2021 · 98 citations · Full text

Medicine, Oncology, Breast Oncology +16